Search clinical trials for: ntrk fusion

Total 1890 results

Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Phase 2 Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors

Advanced Solid Tumors Harboring NTRK Fusion | Primary Central Nervous System Tumors Harboring NTRK Fusion

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors

Metastasis, Neoplasm

China
GCS Ramsay Santé pour l'Enseignement et la Recherche

Not yet recruiting

Evaluation of the Incidence of NTRK Gene Fusion in Adult Brain Tumours (NTRK Fusion)

Glioma

France
Xuanzhu Biopharmaceutical Co., Ltd.

Recruiting

A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors | Locally Advanced or Metastatic Non-small Cell Lung Cancer

China
Bayer

Recruiting

NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes

Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion

Japan
Centre Leon Berard

Recruiting

Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING) (TRacKING)

Cancer | Cancer Metastatic | ALK Fusion Protein Expression | FGFR2 Gene Translocation | FGFR3 Gene Translocation | NTRK Family Gene Mutation | Gene Fusion | ROS1 Gene Translocation | NTRK Gene Fusion Overexpression | ATIC-ALK Fusion Protein Expression | BCR-FGFR1 Fusion Protein Expression | COL1A1-PDGFB Fusion... and other conditions

France, Denmark, Netherlands, Austria, Germany, Italy, United Kingdom, Czechia, Poland, Slovenia, Spain
Fochon Pharmaceuticals, Ltd.

Recruiting

Study of FCN-011 in Patients With Advanced Solid Tumor（Phase I）and NTRK Fusion Positive Advanced Solid Tumor （Phase II）

Advanced Solid Tumor

China
Jiangsu Simcere Pharmaceutical Co., Ltd.

Recruiting

An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.

Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion

China
Nationwide Children's Hospital

Recruiting

A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

High Grade Glioma | Diffuse Intrinsic Pontine Glioma

United States, Australia, Canada, Germany
AnHeart Therapeutics Inc.

Recruiting

Basket Study of AB-106 for the Treatment of Patients With Solid Tumors With NTRK Fusion Gene

Solid Tumor

China
Bayer

Recruiting

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body (ON-TRK)

Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion

United States, Austria, Denmark, Germany, Italy, Norway, Spain, United Kingdom, Brazil, Russian Federation, Switzerland, Taiwan, Canada, China, Australia, Greece, Belgium, Sweden, Korea, Republic of, France, Argentina, Finland, Ireland and more
Memorial Sloan Kettering Cancer Center
Exelixis

Recruiting

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Non-Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent... and other conditions

United States, Puerto Rico
AstraZeneca

Active, not recruiting

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (ORCHARD)

Non-Small Cell Lung Cancer

Denmark, Italy, Spain, United States, Korea, Republic of, Japan, Netherlands, Norway, Sweden
Bayer

Active, not recruiting

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE)

Solid Tumors Harboring NTRK Fusion

United States, Korea, Republic of, China, Japan, India, France, Turkey, Portugal, Spain, Taiwan, Czechia, Sweden, Brazil, Denmark, Singapore, Argentina, Germany, Ireland
Bayer

Active, not recruiting

A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children (SCOUT)

Solid Tumors Harboring NTRK Fusion

United States, China, Poland, Australia, Germany, Japan, Canada, Italy, Czechia, Spain, Turkey, United Kingdom, Sweden, Netherlands, France, Switzerland, Korea, Republic of, Denmark, Ireland, Israel, Ukraine
Regina Elena Cancer Institute
University of Roma La Sapienza; Bambino Gesù Hospital and Research Institute

Active, not recruiting

Three-pronged Centralized Molecular Analysis to Optimize Detection of NTRK1,2,3 Fusions in Thyroid Cancer (NTRK)

Thyroid Cancer

Italy
Pyramid Biosciences

Terminated

Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

Solid Tumor, Adult | Desmoplastic Small Round Cell Tumor | Brain Tumor, Primary

France, United States, Spain, Hong Kong, United Kingdom, Australia, Singapore, Germany, Korea, Republic of, Italy, Denmark
Hoffmann-La Roche

Active, not recruiting

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)

Melanoma | Renal Cell Carcinoma | Adult Solid Tumor | Breast Cancer | Head and Neck Neoplasms | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Neuroendocrine Tumors | Lymphoma, Large-Cell, Anaplastic | Cholangiocarcinoma | Papillary Thyroid Cancer | Sarcomas | Salivary Gland Cancers and other conditions

United States, China, Korea, Republic of, Australia, Taiwan, France, Spain, United Kingdom, Hong Kong, Belgium, Italy, Germany, Japan, Singapore, Netherlands, Poland
Bayer

Completed

A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer

Solid Tumors Harboring NTRK Fusion

United States, Belgium, Italy, Germany, Australia, Spain, Singapore, Denmark, France, Ireland
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

Central Nervous System Neoplasm | Solid Neoplasm | Recurrent Acute Leukemia | Refractory Acute Leukemia | Infantile Fibrosarcoma

United States, Canada
iOMEDICO AG
Roche Pharma AG

Active, not recruiting

Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion (REALTRK)

NTRK Family Gene Mutation

Switzerland, Germany
Bayer

Completed

A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice

Solid Tumors Harboring NTRK Fusion

United States
Bayer

Completed

A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

Solid Tumors Harboring NTRK Fusion

United States
Bayer

Completed

An Observational Study to Learn More About NTRK Gene Fusion Positive in Solid Tumor in Japan

Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion

Japan
Centre Leon Berard
Bayer

Active, not recruiting

A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib (LAROTRACKING)

Metastatic Cancer | Solid Tumor, Adult | Locally Advanced Solid Tumor

France
Centre Leon Berard
Hoffmann-La Roche

Active, not recruiting

RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions. (RNASARC)

Soft Tissue Sarcoma | Metastatic Cancer | Advanced Cancer

France
Bayer

Completed

A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database (EPI VITRAKVI)

Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion | Infantile Fibrosarcoma

France
Jiangsu vcare pharmaceutical technology co., LTD

Completed

Food Effect Study on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects

Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion

China
Institut Bergonié
Bayer

Completed

A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study (NTRK)

Metastatic Solid Tumors

France
Wangjing Hospital, China Academy of Chinese Medical...
Guangdong Provincial Hospital of Traditional Chinese Medicine; Xiyuan Hospital... and other collaborators

Completed

The Study of Chinese Medicine for the Treatment of Chronic Atrophic Gastritis

Chronic Atrophic Gastritis

China
Bayer

No longer available

Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion

Solid Tumors Harboring NTRK Fusion
Bayer

Completed

Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants

Solid Tumors Harboring NTRK Fusion

United States
Bayer

Completed

Study in Healthy Adult Male Participants to Gather Information How the Human Body Absorbs, Distributes and Excretes the Study Drug Selitrectinib Including the Effect of the Interaction of Food With the Study Drug on the Human Body

Solid Tumors Harboring NTRK Fusion

Germany
University of California, San Francisco

Terminated

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

ALK Fusion Protein Expression | Stage III Cutaneous Melanoma | Stage IIIA Cutaneous Melanoma | Stage IIIB Cutaneous Melanoma | Stage IIIC Cutaneous Melanoma | Stage IV Cutaneous Melanoma | ROS1 Fusion Positive | BRAF wt Allele | Invasive Skin Melanoma | MET Fusion Gene Positive | NRAS wt Allele | NTRK1 Fusion... and other conditions

United States
Bayer

Approved for marketing

Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion

Tumors Harboring NTRK Fusion
Ono Pharmaceutical Co. Ltd

Terminated

Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors (ONTRK)

Solid Tumor

United States, United Kingdom
Hoffmann-La Roche

No longer available

Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions

Cancers With NTRK, ROS1, or ALK Gene Fusions

United States
Plexxikon

Terminated

Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors

Solid Tumor | Tenosynovial Giant Cell Tumor | Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutations

United States
Changhai Hospital
West China Hospital; Shandong Provincial Hospital; The First Affiliated Hospital... and other collaborators

Not yet recruiting

Multimodal Endoscopic Image Fusion for Assessing Infiltration in Superficial Esophageal Squamous Cell Carcinoma

Esophageal Neoplasms Malignant

China
Fusion Pharmaceuticals Inc.

Recruiting

FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) (AlphaBreak)

Metastatic Castration-resistant Prostate Cancer

United States
Amsterdam UMC, location VUmc

Recruiting

Assessment of Cardiac Function, Microvascular Function and Cardiac Perfusion in Different Disease Stages of Hypertrophic Cardiomyopathy (FUSION-HCM)

Hypertrophic Cardiomyopathy | Hypertrophic Cardiomyopathy, Obstructive

Netherlands
University of Missouri-Columbia

Recruiting

Baker Gordon Syndrome Natural History Study (BAGOS)

Epilepsy, Generalized | Sleep Disorder | Rare Diseases | Development Delay | Motor Delay | Autism or Autistic Traits | SYT-SSX Fusion Protein Expression

United States
CSL Behring

Not yet recruiting

Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy

Hemophilia B
Poznan University of Medical Sciences

Not yet recruiting

Erector Spinae Plane Block for Cervical Spine Surgery

Spine Fusion | Spine Disease | Spinal Disease

Poland
Samsung Medical Center

Not yet recruiting

Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion

Solid Tumor, Adult

Korea, Republic of
B.Braun Avitum AG

Recruiting

Prospective, Multicentre, Randomized, Controlled, Cross-over Study on the Safety and Performance of the Biologic Fusion Option of DialogiQ Compared to Haemodialysis Without Biologic Fusion in Hypotension Prone Patients on Maintenance Haemodialysis

Renal Dialysis

Italy
Teknimed

Recruiting

BONE SUBSTITUTES OUTCOMES

Bone Resorption

France, Germany
AO Foundation, AO Spine

Not yet recruiting

Durability of Suppl. Rod Constructs-SuppleMentAry Rod Technique for Long-segment Posterior Instrumented Spinal Fusions

Spinal Fusion

United States
Istituto Ortopedico Rizzoli

Not yet recruiting

Mini-invasive Spine Surgery for Neuromuscolar Scoliosis (MISNM)

Surgery | Vertebral Fusion | Spine Deformity | Neuromuscular Scoliosis

Italy

Search clinical trials for: ntrk fusion

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations